Kinnate Biopharma Crescita futura

Future criteri di controllo 0/6

Si prevede che Kinnate Biopharma aumenterà gli utili e i ricavi rispettivamente del 17% e 59.7% all'anno, mentre si prevede che l'EPS crescerà del 33.9% all'anno.

Informazioni chiave

17.0%

Tasso di crescita degli utili

33.9%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	42.4%
Tasso di crescita dei ricavi	59.7%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Good
Ultimo aggiornamento	16 Feb 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

MUN:6KB - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	N/A	-74	-40	-31	3
12/31/2025	N/A	-58	-42	-43	4
12/31/2024	N/A	-66	-55	-74	6
12/31/2023	N/A	-118	-96	-95	6
9/30/2023	N/A	-127	-107	-106	N/A
6/30/2023	N/A	-127	-102	-102	N/A
3/31/2023	N/A	-122	-96	-96	N/A
12/31/2022	N/A	-116	-92	-89	N/A
9/30/2022	N/A	-111	-91	-88	N/A
6/30/2022	N/A	-105	-88	-85	N/A
3/31/2022	N/A	-99	-81	-79	N/A
12/31/2021	N/A	-90	-72	-71	N/A
9/30/2021	N/A	-77	-62	-62	N/A
6/30/2021	N/A	-63	-53	-53	N/A
3/31/2021	N/A	-49	-41	-41	N/A
12/31/2020	N/A	-36	-30	-30	N/A
9/30/2020	N/A	-26	-20	-20	N/A
12/31/2019	N/A	-10	-11	-11	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che 6KB rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che 6KB rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che 6KB rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che 6KB non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che 6KB non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 6KB è previsto essere elevato tra 3 anni

Kinnate Biopharma Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Kinnate Biopharma Files Form 15

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Kinnate Biopharma Inc. Announces Workforce Restructuring

New minor risk - Market cap size

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

Kinnate Biopharma Inc. Appoints Jill DeSimone as Independent Director, Effective on March 1, 2023

Kinnate Biopharma Inc. to Present Trials in Progress Poster for Its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

High number of new and inexperienced directors

Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor

Kinnate Biopharma Inc. Announces Pipeline Update

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from Russell 2000 Growth Index

Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022

High number of new and inexperienced directors

Kinnate Biopharma Inc., Annual General Meeting, Jun 10, 2022

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Its FGFR Inhibitor Product Candidate, KIN-3248

Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

Chief Medical Officer recently bought €308k worth of stock

Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation At the American Association for Cancer Research Annual Meeting

Kinnate Biopharma Inc. to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Kinnate Biopharma Inc. Announces U.S Food and Drug Administration Clearance of Investigational Drug Application for KIN-3248

Kinnate Biopharma Inc. Announces That the First Patient Has Commenced Treatment in its Phase 1 KN-8701 Clinical Trial

Director Stephen Kaldor has left the company

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita